TY  - JOUR
AU  - Fumoleau, Pierre
AU  - Trigo, José Manuel
AU  - Isambert, Nicolas
AU  - Sémiond, Dorothée
AU  - Gupta, Sunil
AU  - Campone, Mario
PY  - 2013
DO  - 10.1186/1471-2407-13-460
UR  - http://hdl.handle.net/10668/1391
T2  - BMC cancer
AB  - BACKGROUNDCabazitaxel is approved in patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-containing regimen. This study evaluated a weekly cabazitaxel dosing regimen. Primary objectives were to report...
LA  - en
PB  - BioMed Central
KW  - Phase I
KW  - Cabazitaxel
KW  - Solid tumour
KW  - Ensayo Clínico Fase I
KW  - Antineoplásicos
KW  - Neoplasias
KW  - Taxoides
KW  - Dosis Máxima Tolerada
KW  - Medical Subject Headings::Publication Characteristics::Study Characteristics::Clinical Trial::Clinical Trial, Phase I
KW  - Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
KW  - Medical Subject Headings::Diseases::Neoplasms
KW  - Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Alicyclic::Cycloparaffins::Cyclodecanes::Taxoids
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose
KW  - Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
KW  - Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
TI  - Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
TY  - research article
ER  -